The Relationship of Adiponectin in Adipose Tissue, Thy-1 in Plaques, and Inflammatory Mediators With Cardiac Diseases

Not Applicable

Completed

• Conditions: Heart Surgery
• Interventions: Procedure: VHD; Procedure: CAD

• Registration Number: NCT02519257
• Lead Sponsor: Far Eastern Memorial Hospital

Brief Summary

Atherosclerosis is an inflammatory process in which immune mechanisms interact with metabolic risk factors to initiate, propagate, and activate lesions in the arterial trees and is known as the main cause of coronary artery disease (CAD). Recently, there are more and more studies highlighted the potential importance of adipose tissue in relation to inflammation effects on CAD pathogenesis. However, it remains unclear whether Thy-1, adiponectin or any other inflammatory mediators in mediastinal adipose tissue contribute to CAD. In this study, we aim to analyze the expression of inflammatory mediators' expression via in vitro assay (3T3-L1 cell culture) and in vivo assay (human adipose tissues).

Detailed Description

In addition, we'd like to investigate the association of the investigators' findings with clinical atherosclerotic risks, medications (statins or antiplatelet), and blood sugar. Now, we've established cell assay and successfully transformed mature adipocyte from 3T3-L1 cells. Besides, there were nighty-six patients enrolled into this study. Flow cytometry of Thy-1 and MCP-1 concentration in cultured medium by ELISA were also analyzed.

Study Timeline

• Study Start: 2008-08
• Primary Completion: 2010-07
• Study Completion: 2010-07
• Status Verified: 2015-08
• Study First Submitted: 2015-08-02
• Study First Submitted QC: 2015-08-06
• Last Update Submitted: 2015-08-06
• Study First Posted: 2015-08-10
• Last Update Posted: 2015-08-10

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 96

Inclusion Criteria

• coronary artery bypass grafting surgery
• valvular surgery

Exclusion Criteria

• liver disease (GPT 2 times greater than normal limits)
• chronic renal insufficiency (Creatinine > 2.0 mg/dL)
• neoplastic diseases
• taking steroids
• congestive heart failure

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
VHD	VHD	Patients with valve diseases proposed to have cardiac operations will be enrolled in this study, but those with congestive heart failure are excluded. Besides, those patients with valve diseases should have patent coronary arteries on coronary angiography.
CAD	CAD	Patients with valve diseases proposed to have cardiac operations will be enrolled in this study, but those with congestive heart failure are excluded. Besides, those patients with valve diseases should have patent coronary arteries on coronary angiography.

Primary Outcome Measures

Name	Time	Method
CD91 (Thy-1)	up to 24 months

Secondary Outcome Measures

Name	Time	Method
CD45	up to 24 months

Trial Locations

Locations (1)

Far Eastern Memorial Hospital; 🇨🇳 New Taipei City, Taiwan